title: Small- and large-fiber neuropathy after 40 years of type 1 diabetes: associations with glycemic control and advanced protein glycation: the Oslo Study.
abstract: OBJECTIVE
  To study large- and small-nerve fiber function in type 1 diabetes of long duration and associations with HbA1c and the advanced glycation end products (AGEs) N-ε-(carboxymethyl)lysine (CML) and methylglyoxal-derived hydroimidazolone.
  
  
  METHODS
  In a long-term follow-up study, 27 persons with type 1 diabetes of 40 ± 3 years duration underwent large-nerve fiber examinations, with nerve conduction studies at baseline and years 8, 17, and 27. Small-fiber functions were assessed by quantitative sensory thresholds (QST) and intraepidermal nerve fiber density (IENFD) at year 27. HbA1c was measured prospectively through 27 years. Serum CML was measured at year 17 by immunoassay. Serum hydroimidazolone was measured at year 27 with liquid chromatography-mass spectrometry.
  
  
  RESULTS
  Sixteen patients (59%) had large-fiber neuropathy. Twenty-two (81%) had small-fiber dysfunction by QST. Heat pain thresholds in the foot were associated with hydroimidazolone and HbA1c. IENFD was abnormal in 19 (70%) and significantly lower in diabetic patients than in age-matched control subjects (4.3 ± 2.3 vs. 11.2 ± 3.5 mm, P < 0.001). IENFD correlated negatively with HbA1c over 27 years (r = -0.4, P = 0.04) and CML (r = -0.5, P = 0.01). After adjustment for age, height, and BMI in a multiple linear regression model, CML was still independently associated with IENFD.
  
  
  CONCLUSIONS
  Small-fiber sensory neuropathy is a major manifestation in type 1 diabetes of 40 years duration and more prevalent than large-fiber neuropathy. HbA1c and the AGEs CML and hydroimidazolone are important risk factors in the development of large- and small-fiber dysfunction in long-term type 1 diabetes.
authors.affiliation: Corresponding author: Kari Anne Sveen, k.a.sveen@medisin.uio.no.
authors.forename: Kari Anne
authors.initials: KA
authors.lastname: Sveen
authors.forename: Bassam
authors.initials: B
authors.lastname: Karimé
authors.forename: Ellen
authors.initials: E
authors.lastname: Jørum
authors.forename: Svein Ivar
authors.initials: SI
authors.lastname: Mellgren
authors.forename: Morten Wang
authors.initials: MW
authors.lastname: Fagerland
authors.forename: Vincent M
authors.initials: VM
authors.lastname: Monnier
authors.forename: Knut
authors.initials: K
authors.lastname: Dahl-Jørgensen
authors.forename: Kristian F
authors.initials: KF
authors.lastname: Hanssen
mesh_terms: D000293:Adolescent; D000328:Adult; D001786:Blood Glucose; D003922:Diabetes Mellitus, Type 1 / Q000150:complications / Q000453:epidemiology* / Q000503:physiopathology*; D003928:Diabetic Nephropathies / Q000453:epidemiology* / Q000209:etiology / Q000503:physiopathology*; D005260:Female; D005500:Follow-Up Studies; D006442:Glycated Hemoglobin / Q000032:analysis; D017127:Glycation End Products, Advanced / Q000097:blood; D006801:Humans; D007093:Imidazoles / Q000097:blood; D008239:Lysine / Q000031:analogs & derivatives / Q000097:blood; D008297:Male; D008875:Middle Aged; D009412:Nerve Fibers / Q000502:physiology*; D011765:Pyruvaldehyde / Q000097:blood; D012684:Sensory Thresholds; D055815:Young Adult
chemical_list: D001786:Blood Glucose; D006442:Glycated Hemoglobin; D017127:Glycation End Products, Advanced; D007093:Imidazoles; D008239:Lysine; D011765:Pyruvaldehyde; C517652:hemoglobin A1c protein, human; C117197:imidazolone; C048496:N(6)-carboxymethyllysine
references.citation: Diabetes. 2009 Dec;58(12):2893-903
references.pmid: 19720799
references.citation: Curr Diab Rep. 2010 Aug;10(4):276-82
references.pmid: 20464532
references.citation: Neurologist. 2008 Jan;14(1):23-9
references.pmid: 18195653
references.citation: Br Med J (Clin Res Ed). 1986 Nov 8;293(6556):1195-9
references.pmid: 3096429
references.citation: N Engl J Med. 2005 Jan 27;352(4):341-50
references.pmid: 15673800
references.citation: J Neurol. 2008 Aug;255(8):1197-202
references.pmid: 18574618
references.citation: Free Radic Biol Med. 2010 Sep 1;49(5):847-56
references.pmid: 20541005
references.citation: Diabetes Care. 2010 May;33(5):1090-6
references.pmid: 20150297
references.citation: Diabetologia. 1997 Dec;40(12):1380-7
references.pmid: 9447944
references.citation: J Diabetes Complications. 2013 Mar-Apr;27(2):141-9
references.pmid: 23153673
references.citation: Neurology. 2004 Mar 9;62(5):774-7
references.pmid: 15007129
references.citation: J Neurol Neurosurg Psychiatry. 1976 Nov;39(11):1071-5
references.pmid: 188989
references.citation: Arch Intern Med. 1997 Sep 8;157(16):1851-6
references.pmid: 9290544
references.citation: Diabetologia. 2012 Mar;55(3):795-800
references.pmid: 22193513
references.citation: Diabetologia. 2010 Jun;53(6):1093-8
references.pmid: 20237754
references.citation: Diabetes Care. 2006 Oct;29(10):2282-8
references.pmid: 17003307
references.citation: Diabetologia. 1994 Jun;37(6):579-84
references.pmid: 7926342
references.citation: Eur J Neurol. 2006 Feb;13(2):105-11
references.pmid: 16490039
references.citation: Acta Endocrinol Suppl (Copenh). 1987;284:1-38
references.pmid: 3300128
references.citation: Nat Med. 2012 Jun;18(6):926-33
references.pmid: 22581285
references.citation: Diabetes Care. 2010 Jul;33(7):1585-90
references.pmid: 20587724
references.citation: Diabetes Metab Res Rev. 2011 Oct;27(7):620-8
references.pmid: 21695763
references.citation: Int J Cardiol. 2007 Apr 25;117(2):287-91
references.pmid: 16889854
references.citation: Diabetes Care. 1998 Nov;21(11):1997-2002
references.pmid: 9802757
references.citation: Diabetes Care. 2003 Aug;26(8):2400-4
references.pmid: 12882869
references.citation: J Clin Neurophysiol. 1999 Sep;16(5):462-71
references.pmid: 10576229